Revolution Medicines, Inc. Warrant (RVMDW)

Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.

Tango Therapeutics reported a steep decline in Q2 2025 revenue and wider net losses, with ongoing clinical trials in targeted oncology therapies and the early termination of its Gilead partnership.

Three healthcare stocks, Aveanna Healthcare Holdings Inc, Revolution Medicines, and Fulcrum Therapeutics, have seen significant price gains recently, indicating they may be overbought and could pose risks to investors focused on momentum trading.